医学
核受体
非诺贝特
内分泌学
内科学
兴奋剂
过氧化物酶体增殖物激活受体α
罗格列酮
过氧化物酶体
类降脂药
作者
Ekaterina A. Ivanova,Veronika A. Myasoedova,Alexandra А. Melnichenko,Alexander N. Orekhov
标识
DOI:10.2174/1381612823666161118145850
摘要
Peroxisome proliferation-activated receptors (PPARs) are ligand-activated transcription factors that mainly regulate genes responsible for fatty acid (FA) and energy metabolism. There are three members of the PPAR family, PPAR-α, PPAR- β/δ and PPAR-γ. All three isoforms have therapeutic potential for treatment of cardiovascular disorders, and PPAR agonists are currently being actively studied in pre-clinical and clinical trials. PPAR γ agonists, main tissue expressing isoform, have potential to influence on inflammation processes, reduce oxidative stress, improve endothelial function and plays an important role in lipid metabolism. PPAR-γ agonists are used as insulin sensitizers for treatment of diabetes; however, there is accumulating evidence that their clinical application can be broadened. The wide spectrum of PPAR-γ activation effects may be beneficial for treatment of various cardiovascular conditions as atherosclerosis, hypertension and aortic aneurysm, including surgical interventions. In this Review we will discuss the implication of PPAR-γ in the cardiovascular system and potential role of PPAR-γ agonists in treatment of conditions associated with high cardiovascular risks.
科研通智能强力驱动
Strongly Powered by AbleSci AI